Clinical Trials · NCT07479784
Octreotide Microspheres for Preventing Pancreatic Fistula
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Shanghai Zhongshan Hospital
- Enrollment
- 230
- Start date
- Apr 2026
- Locations
- See registry
- Primary endpoint
- Incidence of CR-POPF at 60 days postoperatively